Literature DB >> 22930497

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Anu Osinusi1, Aarthi Chary, Mark A Winters, Susanna Naggie, Henry Masur, Michael A Polis, Shyam Kottilil, Mark Holodniy.   

Abstract

Recent studies have demonstrated that IL28B polymorphisms predict therapeutic responses in chronic hepatitis C virus (HCV)-treated patients; however, the effect on HCV viral diversity, particularly on the HCV protease gene, is not clear. This study sought to evaluate the effect of IL28B polymorphisms on HCV diversity at NS3/4 protease region, which may influence therapeutic response to an HCV protease inhibitor based regimen. Twenty-two patients co-infected with HIV and HCV genotype 1, treatment-naïve on stable HIV antiretroviral therapy initiating interferon-based treatment were evaluated. Plasma HCV NS3 gene diversity was analyzed by clonal analysis at baseline and end of treatment. IL28B (rs12979860) genotypes were tested for associations with virologic outcomes and diversity parameters. There was similar baseline NS3 diversity in patients with CC (favorable) genotype compared to those with CT/TT (unfavorable) genotypes. There was no significant association between IL28B genotype and baseline NS3 nucleotide p-distance, dS-dN, amino acid p-distance, or nucleotide changes. Among patients without a sustained virologic response, between baseline and follow-up there was a significant trend towards decreased diversity after treatment among patients with favorable genotype, which was not observed in unfavorable genotypes. In patients treated with peginterferon/ribavirin therapy, IL28B polymorphism was not associated with enhanced NS3 diversity at baseline. Among non-SVR patients with the less favorable genotype, there was no change in diversity after treatment. This suggests that IL28B genotype is unlikely to have a negative impact on subsequent HCV PI efficacy in patients co-infected with HIV and HCV patients who have previously failed HCV therapy. Published 2012 Wiley Periodicals, Inc. This article is a U.S. Government work and is in the public domain in the United States of America.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930497      PMCID: PMC3690569          DOI: 10.1002/jmv.23376

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  31 in total

1.  HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.

Authors:  Isabella Abbate; Oreste Lo Iacono; Rosa Di Stefano; Giuseppina Cappiello; Enrico Girardi; Roberta Longo; Donatella Ferraro; Giorgio Antonucci; Vito Di Marco; Mariacarmela Solmone; Antonio Craxì; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

2.  Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.

Authors:  Mark A Winters; Aarthi Chary; Robert Eison; David Asmuth; Mark Holodniy
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

Review 3.  Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.

Authors:  Aarthi Chary; Mark Holodniy
Journal:  Rev Recent Clin Trials       Date:  2010-09

4.  Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Norma I Rallón; Susanna Naggie; José M Benito; José Medrano; Clara Restrepo; David Goldstein; Kevin V Shianna; Eugenia Vispo; Alex Thompson; John McHutchison; Vincent Soriano
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

5.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

6.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

7.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

8.  Hepatitis C virus mutation affects proteasomal epitope processing.

Authors:  Ulrike Seifert; Heike Liermann; Vito Racanelli; Anne Halenius; Manfred Wiese; Heiner Wedemeyer; Thomas Ruppert; Kay Rispeter; Peter Henklein; Alice Sijts; Hartmut Hengel; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

10.  Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

Authors:  Chihiro Morishima; Stephen J Polyak; Ranjit Ray; Michael C Doherty; Adrian M Di Bisceglie; Peter F Malet; Herbert L Bonkovsky; Daniel G Sullivan; David R Gretch; Alan L Rothman; Margaret James Koziel; Karen L Lindsay
Journal:  J Infect Dis       Date:  2006-02-22       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.